The projected epidemiological effect of Xpert MTB/RIF might be overestimated, so this fascinating and promising new tool is unlikely to be the magic bullet that paves the way towards tuberculosis elimination.

To prioritize an agenda for implementing TB diagnostics that centers upon the patient with TB symptoms and highlights patient well-being and cure.

Letter to Cepheid cites continued cost of machines, Russia, China cartridge costs of five to six times negotiated price, and more.

In view of the present and future requirements of global tuberculosis control, a sustained fight against tuberculosis now needs enhanced investment.

Newly discovered mutations help tuberculosis to stay infectious while evolving resistance to multiple drugs.

UNITAID reports exploring the patent landscapes and possible access issues relating to bedaquiline, SQ109, AZD5847, sutezolid, delamanid and PA-824.

The paper seeks to offer suggestions for compensation policy reform, drawn from a comparative analysis of relevant practices in select countries around the world with similar issues pertaining to mining and health justice.

A second systematic review of a diagnostic test for TB endorsed by WHO, has confirmed the accuracy of the test. Xpert® MTB/RIF is more accurate than smear microscopy for diagnosing TB and also accurate for detecting rifampicin resistance.

After 40 years of no new therapies, approval of bedaquiline and delamanid for the treatment of tuberculosis is a cause for optimism. But is that hope well founded?

A leaked email shows that a plan for a campaign to scuttle the South African government's draft intellectual property policy was about to proceed, despite a denial by the pharmaceutical industry that it had approved the campaign.